Ibrahim Mohamed Elsayed Eltahan

Dr. Ibrahim Mohamed Elsayed Eltahan

Department of Cardiology, Menoufia University Hospitals, Shibīn al Kawm, Al Minūfīyah, Egypt
orcid
Postgraduate Researcher, M.B.B.Ch, MSc in progress, Menoufi...

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Journal of Cardiovascular Echography
Verified
Journal Article
Open access
IEIbrahim Mohamed Elsayed Eltahan
Ibrahim Mohamed Elsayed Eltahan
ASAmany R. M. Serag
Amany R. M. Serag
MKMohamed Y. Abd El Khalek
Mohamed Y. Abd El Khalek
HAHend M. Abdou
Hend M. Abdou
Background: Peripheral arterial disease shares common pathophysiological mechanisms with coronary artery disease (CAD), including inflammation and atherosclerosis. Carbohydrate antigen 125 (CA-125), previously known as a tumor marker, has been suggested to be elevated in patients with heart failure and CAD. Aim: The aim of this study was to assess the correlation of serum tumor marker carbohydrate antigen 125 with ankle–brachial index (ABI) in patients with CAD. Materials and Methods: A prospective study was conducted on 60 CAD patients. Based on ABI, they were grouped into low ABI (≤0.9) and normal ABI (1–1.4). Serum CA-125 and high-sensitivity C-reactive protein (hs-CRP) were measured, and transthoracic echocardiographic parameters were evaluated. Results: CA-125 was significantly higher in patients with low ABI compared to those with normal ABI (13.17 ± 4.48 vs. 10.03 ± 3.18 U/ml, P = 0.003). CA-125 was negatively correlated with ABI ( r = −0.887, P < 0.001) and positively with hs-CRP ( r = 0.696, P < 0.001). Conclusion: Serum CA-125 is a readily available biomarker that may have utility as a supplementary indicator of atherosclerotic burden and vascular risk in patients with CAD.